Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003-2005

Parkinsonism and Related Disorders

Volumn 14, Issue 5, 2008, Pages 420-425

  Trifirò, Gianluca ^a,d   Savica, Rodolfo ^a   Morgante, Letterio ^a   Vanacore, Nicola ^b   Tari, Michele ^c   Moretti, Salvatore ^c   Galdo, Mariella ^c   Spina, Edoardo ^a,d   Caputi, Achille P ^a,d   Arcoraci, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Caserta 1 Local Health Service   (Italy)

^d IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Anti Parkinson drugs; Dopamine agonist; Levodopa; Parkinson's disease; Prevalence of use

Indexed keywords

ANTIPARKINSON AGENT; BIPERIDEN; BORNAPRINE; BROMOCRIPTINE; CABERGOLINE; DOPA DECARBOXYLASE INHIBITOR; LEVODOPA; METIXENE; PERGOLIDE; PRAMIPEXOLE; PROCYCLIDINE; ROPINIROLE; TRIHEXYPHENIDYL;

ARTICLE; CLINICAL PRACTICE; GENERAL PRACTITIONER; ITALY; MONOTHERAPY; PARKINSON DISEASE; PRESCRIPTION; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HUMANS; ITALY; MALE; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 46949106028     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.10.010     Document Type: Article

References (35)

1. Rosati G., Granieri E., Pinna L., Aiello I., Tola R., De Bastiani P., et al. The risk of Parkinson's disease in Mediterranean people. Neurology 30 (1980) 250-255
2. Morgante L., Rocca W.A., Di Rosa A.E., De Domenico P., Grigoletto F., Meneghini F., et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 42 (1992) 1901-1907
3. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 (1977) 345-349
4. Fahn S. "On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effects of intramuscular pyridoxine. Neurology 24 (1974) 431-441
5. Marsden C.D., and Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1 (1976) 292-296
6. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., and Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 (2000) 1484-1491
7. Brooks D.J. Dopamine-agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 68 (2000) 685-690
8. Fisher P.A. Treatment strategies in Parkinson's disease after a quarter century experiences with L-Dopa therapy. J Neurol Transm Suppl 46 (1995) 381-399
9. Uitti R.J., and Ahlskog J.E. Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 5 (1996) 369-388
10. Earley C.J. Clinical practice. Restless legs syndrome. N Engl J Med 348 (2003) 2103-2109
11. Pritchett A.M., Morrison J.F., Edwards W.D., Schaff H.V., Connolly H.M., and Espinosa R.E. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 (2002) 1280-1286
12. Pinero A., Marcos-Alberca P., and Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353 (2005) 1976-1977
13. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., and Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 (2007) 39-46
14. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson's disease. Drugs Aging 22 (2005) 731-740
15. Verhagen Metman L., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., and Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 (1998) 1323-1326
16. Myllyla V.V., Sotaniemi K.A., Vuorinen J.A., and Heinonen E.H. Selegiline in de novo parkinsonian patients: the Finnish study. Mov Disord 1 Suppl. 8 (1993) S41-S44
17. Merello M., Lees A.J., Webster R., Bovingdon M., and Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57 (1994) 186-189
18. Leoni O., Martignoni E., Cosentino M., Michielotto D., Calandrella D., Zangaglia R., et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 11 (2002) 149-157
19. Menniti-Ippolito F., Spila-Alegiani S., Vanacore N., Bonifati V., Diana G., Meco G., et al. Estimate of parkinsonism prevalence through drug prescription histories in the Province of Rome, Italy. Acta Neurol Scand 92 (1995) 49-54
20. Lai B.C., Schulzer M., Marion S., Teschke K., and Tsui J.K. The prevalence of Parkinson's disease in British Columbia, Canada, estimated by using drug tracer methodology. Parkinsonism Relat Disord 9 (2003) 233-238
21. Askmark H., Antonov K., and Aquilonius S. The increased utilisation of dopamine agonists and the introduction of COMT inhibitors have not reduced levodopa consumption - a nationwide perspective in Sweden. Parkinsonism Relat Disord 9 (2003) 271-276
22. Lawrenson R., Williams T., and Farmer R. Clinical information for research: the use of general practice databases. J Pub Health Med 21 (1999) 299-304
23. Piacentini N., Trifiro G., Tari M., Moretti S., Arcoraci V., and UVEC group. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 61 (2005) 615-620
24. Trifiro G., Corrao S., Alacqua M., Moretti S., Tari M., UVEC group, et al. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 62 (2006) 582-590
25. Trifirò G., Barbui C., Spina E., Moretti S., Tari M., Alacqua M., et al. Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004. Pharmacoepidemiol Drug Saf 16 (2007) 552-559
26. Totaro R., Marini C., Pistoia F., Sacco S., Russo T., and Carolei A. Prevalence of Parkinson's disease in the L'Aquila district, central Italy. Acta Neurol Scand 112 (2005) 24-28
27. Vanacore N., Bianchi C., Da Cas R., and Rossi M. Use of antiparkinsonian drugs in the Umbria Region. Neurol Sci 24 (2003) 221-222
28. Beghi E., Monticelli M.L., Sessa A., and Simone P. The prevalence of parkinsonism in Italy: an epidemiological survey of the disease in general practice. The Italian General Practitioner Study Group (IGPSG). Mov Disord 9 (1994) 403-408
29. Spila-Alegiani S., Diana G., Menniti-Ippolito F., and Raschetti R. Anticholinergic antiparkinsonian therapy in outpatients treated with neuroleptic drugs: a prescription survey. Eur J Clin Pharmacol 48 (1995) 513-517
30. Da Cas R., Ruggeri P., Romagnoli C., Rossi M., Abraha I., Di Loreto P., et al. Prescrizione farmaceutica in Umbria. Analisi dei dati relativi al 2005. Rapporti ISTISAN 2006, n 6/41 Available from:. http://www.iss.it [accessed 21.07.07]
31. Schade R., Andersohn F., Suissa S., Haverkamp W., and Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 (2007) 29-38
32. Miyasaki J.M., Shannon K., Voon V., Ravina B., Kleiner-Fisman G., Anderson K., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 996-1002
33. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (2006) 983-995
34. Lega italiana per la lotta contro la malattia di Parkinson, le sindromi extrapiramidali e la demenza (LIMPE). Guidelines for the treatment of Parkinson's disease. Neurol Sci 24 (2003) S165-S213
35. Haynes R.B., McKibbon A., and Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 348 (1996) 383-386